← Back to Search

Other

aumolertinib for Liver Damage

Phase 1
Waitlist Available
Research Sponsored by EQRx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose
Awards & highlights

Study Summary

This trial will study the effects of a new drug, EQ143, on people with severe liver impairment. For each person with severe liver impairment enrolled, a corresponding healthy person will be enrolled as well. EQ143 will be given as a single dose, and participants will remain in the study center for 5 days for blood sampling and safety monitoring. There will be follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.

Eligible Conditions
  • Liver Damage

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK Parameter: AUC0-t of EQ143
PK Parameter: AUC0-t of metabolite, HAS719
PK Parameter: AUCinf of EQ143
+4 more
Secondary outcome measures
Number of Participants with Adverse Event
PK Parameter of EQ143: Time to peak concentration (tmax)
PK Parameter of EQ143: apparent volume of distribution (Vz/F)
+12 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: AumolertinibExperimental Treatment1 Intervention
single dose oral 55mg of aumolertinib
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
aumolertinib
2021
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

EQRx, Inc.Lead Sponsor
3 Previous Clinical Trials
145 Total Patients Enrolled
EQRx International, Inc.Lead Sponsor
3 Previous Clinical Trials
8 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143
2022. "An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05199610.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top